54.01
-0.09(-0.17%)
Currency In USD
| Previous Close | 54.1 |
| Open | 55 |
| Day High | 55.28 |
| Day Low | 53.47 |
| 52-Week High | 62.4 |
| 52-Week Low | 29.17 |
| Volume | 2.05M |
| Average Volume | 2.05M |
| Market Cap | 10.1B |
| PE | -11.95 |
| EPS | -4.52 |
| Moving Average 50 Days | 42.72 |
| Moving Average 200 Days | 40.01 |
| Change | -0.09 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $1,868.86 as of October 21, 2025 at a share price of $54.01. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 3 years ago, it would be worth $2,905.33 as of October 21, 2025 at a share price of $54.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
GlobeNewswire Inc.
Oct 17, 2025 12:00 AM GMT
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and D
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
GlobeNewswire Inc.
Sep 29, 2025 1:00 PM GMT
REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
GlobeNewswire Inc.
Sep 10, 2025 8:02 PM GMT
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial clinical results for daraxonrasib monotherapy and daraxo